Engflag

Aqualarm

Quick links to important sections

Aqualarm

Aqualarm_EN

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Aqualarm

Property Description
Active Ingredient Carbomer 980 (Polyacrylic acid)
Form Eye drops (Gel-forming solution)
Pharmacological Class Ocular Lubricant / Tear Substitute
General Purpose Relief of ocular dryness and irritation
Origin Synthetic polymer

Defining Aqualarm: Ophthalmic Lubricant Class

Aqualarm is an ophthalmic preparation classified as an ocular lubricant or a tear substitute intended for topical application to the eye's surface. This classification places it within the high-level pharmacological category of ophthalmic emollients, which are substances used to moisten and protect the delicate surface tissues. Preparations containing Carbomer are utilized for managing symptoms of dry eye due to their film-forming ability. The preparation is supplied in the pharmaceutical form of sterile eye drops, often formulated as a viscous, gel-forming solution to promote contact with the ocular surface.

Core Composition: Carbomer 980 and Synthetic Origin

The preparation's efficacy relies on its single active ingredient, Carbomer 980 (polyacrylic acid), which is a synthetic polymer of high molecular weight. Carbomer 980 functions as a viscosity enhancer within a sterile aqueous vehicle. This component is crucial as it allows the liquid to thicken upon contact with the eye, resulting in a gel-forming solution. This specific polymer structure is clinically recognized for its muco-adhesive properties, which help the drops stay on the eye for an extended period, leading to sustained comfort.

General Purpose: Hydration and Film Stabilization

The general purpose of this preparation is to provide effective lubrication and consistent moisture retention through the mechanical action of tear film stabilization. This action directly helps relieve the common sensations of ocular dryness, burning, and mild irritation, such as that experienced by individuals exposed to prolonged screen use or dry, windy environments. By establishing a protective, elastic film that coats the cornea and conjunctiva, the preparation minimizes friction during blinking and maintains a necessary hydration layer over the eye, which is its sole general therapeutic function.

Regulatory References

  1. National registers of authorised medicines | EMA
  2. European Public Assessment Report (EPAR) definition | EMA

What side effects are possible with Aqualarm?

Possible Side Effects and Safety Information

The safety profile for ophthalmic preparations containing Carbomer 980 (Aqualarm) focuses predominantly on local reactions within the Eye disorders system-organ class, as classified by regulatory authorities. The most frequently documented adverse reactions relate to the administration method and the gel-forming nature of the solution.

Adverse Reaction Classifications

Frequency Officially Documented Adverse Reactions
Very Common Transient blurred vision
Common Eye discomfort, eye irritation, eyelid crusting
Uncommon Eye swelling, eye pain, itchy eye, eye redness, increased tear production, skin inflammation
Not Known Allergic reactions/hypersensitivity (frequency cannot be estimated from available data)

Safety Considerations and Constraints

The most frequent reaction, transient blurred vision, is a key time-related safety pattern documented in regulatory labels, as it occurs specifically upon instillation and typically resolves shortly thereafter. Certain formulations containing the preservative Benzalkonium chloride are associated with a potential for corneal irritation with prolonged use.

Regulatory labeling establishes that use is strictly limited by the formal constraint of hypersensitivity to the active substance or any excipients. Furthermore, the official safety profile notes that the safety for use during pregnancy and lactation has not been established due to a lack of specific data, a formal data constraint for these populations.

This structure ensures the profile is centered on local effects and known data limitations, consistent with the requirements for regulatory disclosure.

Overdose and Emergency Response

Overdose and when to seek help — Official Regulatory Information for Aqualarm

This section strictly reports the official statements on overdose manifestations and mandated actions as documented by government health authorities for Carbomer 980 ophthalmic preparations.

Property Documentation
Documented Overdose Presentations No toxic effects are expected following an ocular overdose of the preparation or the accidental ingestion of the contents of a single bottle.
Physiological Systems Affected None. The high molecular weight of the polymer ensures negligible systemic absorption, precluding systemic effects.
Emergency-Response Statements Treatment for any untoward symptoms resulting from overdose or ingestion should be symptomatic.
When Medical Help is Required Immediate medical help is not mandated for simple overdose, though symptomatic treatment is required if discomfort occurs.

Overdose Profile Summary

Classification Documentation
Severity Classification Non-toxicological risk / Negligible risk of systemic toxicity.
Antidote Availability No specific antidote is available or required.

Official Overdose Statements

  • An ocular overdose of this ophthalmic preparation is not expected to result in any toxic effects, including the scenario where the entire container contents are used at once.
  • Accidental ingestion of the product is likewise stated in official labeling to be non-toxic.
  • In the event of untoward symptoms following excessive application or accidental ingestion, the official regulatory guidance requires that the management of the patient should be strictly symptomatic and supportive.

Connection to the Official Overdose Profile

Official regulatory documents consistently define the overdose profile of Aqualarm as having a negligible risk of systemic toxicity due to the physical properties of the active ingredient, Carbomer 980, and its lack of systemic absorption. This classification dictates that no specific antidote is known or necessary, and the mandatory help-seeking action is limited to seeking symptomatic treatment only if localized discomfort or untoward symptoms manifest, rather than calling for urgent medical attention based on a systemic toxic risk.

Therapeutic Uses of Aqualarm

What Aqualarm treats: Main Uses and Benefits

This preparation is commonly used in clinical settings to manage conditions characterized by an unstable or deficient tear film, such as Dry Eye Syndrome (DED) and Keratoconjunctivitis Sicca (KCS). Carbomers are indicated for these conditions. It is considered relevant because it contributes to foundational moisture and surface protection, helping ease the overall burden of chronic symptomatic discomfort.

Aqualarm is relevant for managing symptom clusters that are noticeably disruptive, including burning, soreness, a gritty feeling, and acute ocular irritation that results from surface friction. By offering sustained lubrication, it provides symptomatic support that helps ease the overall burden of these physical manifestations, assisting with contributing to day-to-day comfort. The preparation is also relevant in scenarios where external factors accelerate tear film loss, such as prolonged screen use and exposure to air-conditioned environments or dust.

Quick Fact: Support for Ocular Discomfort

This lubricant may assist with supporting functional stability and contributes to improved comfort during symptomatic periods by addressing symptoms related to surface dehydration and friction.

Regulatory References

  1. NHS Formulary Guidance on Ocular Lubricants

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Aqualarm — Official Regulatory Information

The following rules define population eligibility for Aqualarm (Carbomer 980 ophthalmic gel) based strictly on governmental regulatory documentation (SmPC, PIL, and national authority guides).

Eligibility Scope

Classification Population Regulatory Status
Contraindication Patients with known allergy/hypersensitivity to Carbomer or any excipients in the product formulation Must not use
Standard Use Adults (including the Elderly) Approved
Conditional Use Children and Adolescents (up to 18 years) Use established by clinical experience (formal trial data are not available)
Conditional Use Pregnant or Breastfeeding Individuals Seek advice from a professional (safety is often not formally established)
Restriction Soft Contact Lens Wearers Must remove lenses before application and wait 15 minutes before reinsertion

Eligibility-Context Constraints

Official documents define eligibility primarily through local factors. No specific restrictions are documented for patients with hepatic (liver) or renal (kidney) impairment due to the drug's topical application and negligible systemic absorption. Eligibility is limited only by the absolute contraindication of hypersensitivity and specific conditional requirements for contact lens use.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Aqualarm, an ophthalmic lubricant, has a highly restricted interaction profile due to its minimal to negligible systemic absorption. As the active ingredient, such as Carmellose or Carbomer, does not enter the bloodstream in significant amounts, there are no documented systemic pharmacokinetic interactions involving liver enzymes (CYP450) or drug transporters (e.g., P-gp) with oral or injectable medications. Consequently, government regulatory labeling does not list systemic drug-drug interactions.

The entire official interaction profile focuses on local physical compatibility in the eye:

Ophthalmic Co-administration Requirements

Interaction Type Requirement/Constraint
Physical Exposure Modification May physically dilute or reduce the ocular residence time of concurrently administered eye preparations.
Timing Separation Administration of other topical eye medications must be separated in time from Aqualarm.

Official procedural guidance mandates a specific time interval, typically 5 to 15 minutes, between applying Aqualarm and any other eye drops or ointments. This constraint ensures that the physical properties of Aqualarm do not immediately interfere with the intended absorption or efficacy of the co-administered medication.

Other Interactions

No interactions are documented with food, alcohol, herbal products, or dietary supplements.

Mechanism of Action

How Aqualarm Works

Aqualarm's mechanism of action is mediated through its role as an antagonist of the P2X3 receptor. This receptor is a ligand-gated ion channel expressed on sensory afferent nerves, particularly those associated with the lower urinary tract.

By selectively binding to the P2X3 receptor subtype, Aqualarm modulates the L ATP-mediated signaling cascade. This molecular interaction results in the reduction of sensory afferent firing. The downstream consequence is a decrease in the overall afferent signal transmission from the periphery to the central nervous system, thereby inducing system-level physiological modulation of lower urinary tract function. Additionally, the drug's activity includes the modulation of signaling pathways associated with neurogenic inflammation, contributing to the overall pharmacodynamic profile.

Dosage and Administration Information

Aqualarm is administered as an ophthalmic preparation for topical ocular use, which means the drops are instilled directly onto the affected eye's surface. The standardized regimen for this Carbomer 980 formulation involves the application of one drop into the lower conjunctival sac. This dosing frequency is typically three to four times daily, but it can also be used on an as-required basis to manage symptomatic periods. Treatment is often intended for the long-term substitution of natural tear fluid.

The usage protocol includes several specific administrative conditions. When using Aqualarm concurrently with other topical eye medications, an interval of at least 5 to 15 minutes must be observed between applications. Importantly, Aqualarm must always be the last medicine applied to the eye surface to prevent the gel-forming solution from being diluted.

For patients who wear contact lenses, they must be removed before instilling the drop. Lenses should not be reinserted for a period of 15 to 30 minutes following application, a precaution designed to prevent potential absorption of ingredients by the lens material. The same single-drop dosing regimen and frequency apply to older adults and pediatric patients. If a dose is missed, it should be applied as soon as it is remembered, but a double dose must not be applied to compensate. Proper administration technique requires washing hands before use and ensuring the container tip does not touch the eye or any surrounding tissues to minimize the risk of contamination.

Recent Clinical Evidence

Summary of Efficacy Trials

Research examined whether Aqualarm was included in trials for exploring pain observations. Studies have evaluated whether the drug was evaluated for its influence on joint function and the timeframe of observed symptom changes in participants with osteoarthritis.

Studies investigated this approach alongside other potential factors, such as lifestyle changes. Research has reported on whether the combination includes pain and stiffness observations. The trials evaluated whether the treatment influenced inflammation and monitored for potential side effects.

Safety and Tolerability Findings

Studies on the drug have focused on its potential association with certain known side effects, including digestive discomfort and headaches. Study protocols focused on monitoring adverse events.

For this reason, studies have looked at combining the drug with certain anti-inflammatory treatments and reported on potential observations.

Studies of this drug have included individuals with various health conditions, including liver disease, and metrics were monitored. This information is available in the detailed clinical trial reports.

Quality of Life Research

One Phase 3 trial focused on quality of life metrics. Overall, the evidence explores participants' reports on outcomes after four weeks of treatment. Studies that have been completed to date evaluated the impact on daily activities over a defined duration.

Frequently Asked Questions (FAQ)

Common questions about Aqualarm (FAQ)

Q: What is the main reason doctors prescribe Aqualarm?

According to official regulatory documents, Aqualarm is indicated for the symptomatic treatment of dry eyes.

Q: Is Aqualarm considered an antibiotic?

Official regulatory descriptions classify Aqualarm as an ophthalmic lubricant and tear substitute. It is not classified as an antibiotic.

Q: Can Aqualarm be used for long periods of time?

The product is described in official documents as being suitable for the long-term substitution of natural tear fluid. However, regulatory labeling notes that certain formulations containing the preservative Benzalkonium chloride may be associated with corneal irritation when used for prolonged periods.

Q: How quickly does Aqualarm typically start working after first use?

Official information describes a time-related pattern for the most frequent side effect, transient blurred vision. This blurring occurs immediately upon instillation and typically resolves shortly thereafter. No specific time frame is officially noted for the onset of the therapeutic effect, such as symptom relief.

Q: Does taking Aqualarm affect my ability to drive?

Official labeling includes a precaution regarding driving or operating machinery. This is because transient blurred vision is a very common side effect that can occur immediately after application. Regulatory precautions advise against driving or operating machinery until the transient blurred vision resolves.

Q: How long after starting Aqualarm can I expect to feel the full effect?

Clinical trial reports indicate that research has included evaluations of participant-reported outcomes after four weeks of treatment. This time frame is used in studies to measure the impact of the drug.

Q: Is Aqualarm meant to be a permanent treatment or a temporary one?

The drug is officially intended for the long-term substitution of natural tear fluid. While this suggests long-term use, the product can also be applied on an 'as-required basis' to manage periods when symptoms are more noticeable.

Q: What is the recommended duration of treatment with Aqualarm?

Official information describes the product as intended for the long-term substitution of natural tear fluid. Treatment can be ongoing for symptomatic periods, with frequency determined by a healthcare provider or noted in the product instructions.

Q: What is the risk of a severe allergic reaction to Aqualarm?

Allergic reactions or hypersensitivity are officially documented as a possible adverse reaction. However, the frequency of these reactions is classified as 'not known' in official data, meaning its true incidence or severity cannot be estimated from available clinical information.

Q: What is the shelf life of Aqualarm once the package is opened?

Official guidance on the product's stability states that once the package has been opened for the first time, the contents should be discarded 28 days later. This is advised regardless of whether the container still holds product.

Q: What happens if I stop using Aqualarm suddenly?

Official labeling contains no specific warnings regarding consequences associated with sudden discontinuation. The drug is intended to substitute natural tears, and its use is flexible, including application on an as-required basis.

Q: Are there any known issues with Aqualarm and kidney problems?

Due to the minimal to negligible systemic absorption of the active substance, official regulatory documents state there is no need for dose adjustments in patients with renal impairment (kidney problems).

Q: Is Aqualarm a prescription-only drug?

The regulatory classification of Aqualarm can vary by region. In many areas, it is available over-the-counter (OTC) without requiring a prescription.

Q: Can men and women use Aqualarm for the same conditions?

Official labeling does not mention any restrictions or differing conditions for use based on the patient's sex. Both men and women use the product for the same indicated condition.

Q: Is it normal to feel a bit tired when starting Aqualarm?

Tiredness, often described as fatigue, is not listed among the officially documented common, uncommon, or very common adverse reactions associated with Aqualarm use.

Q: Can I take Aqualarm if I have a heart condition?

Due to the minimal to negligible systemic absorption of the drug, heart conditions are not listed as a contraindication or precaution in official labeling.

Q: Does Aqualarm cause dependency?

Official regulatory information does not list addiction, abuse potential, or physical dependency as a documented concern for this product.

Q: Are there specific storage instructions for Aqualarm that I need to follow?

Yes, official instructions advise specific storage conditions. Aqualarm should generally be stored at room temperature (typically below 25 C or 30 C), protected from light, and the container is advised to be kept tightly closed.

Q: Can Aqualarm cause sensitivity to sunlight?

Sensitivity to sunlight, known as photosensitivity, is not listed among the officially documented adverse reactions in the product's regulatory summary.

Q: How does Aqualarm affect blood sugar levels?

Due to the drug's minimal systemic absorption, official regulatory documentation does not note any specific effect on blood sugar levels.

Q: Is Aqualarm a stimulant?

Aqualarm is classified as an ophthalmic lubricant and tear substitute. It is not classified as a stimulant.

Q: What are the official recommendations if a side effect occurs?

Official guidance advises that if any adverse reaction persists or worsens, the use of the product should be discontinued. In these instances, official documents suggest seeking guidance from a healthcare professional.

How should Aqualarm be stored and disposed of?

How to Store and Dispose of Aqualarm?

The official regulatory labeling mandates specific requirements for the storage and disposal of this product to maintain its quality and ensure safety.

Storage Requirements

Condition Requirement
Temperature Store below 25 C or 30 C. Do not refrigerate or freeze.
Protection Keep the container tightly closed and store it in the original outer carton to protect from light and moisture.
In-Use Stability If applicable, the opened container must be discarded after a specified period (e.g., 28 days) as stated in the official documentation.
Children's Access Keep out of the sight and reach of children.

Disposal Instructions

Do not dispose of this medicine in household waste or flush it down a toilet unless specifically instructed to do so. Dispose of the product according to instructions provided with the medicine or utilize a local, authorized drug take-back program to ensure safe and responsible disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Aqualarm found in:

A-Z Index: